This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (18)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Early Treatment Diabetic Retinopathy Study Report 16

Emily Y. Chew, MD; George A. Williams, MD; Thomas C. Burton, MD; Franca B. Barton, MS; Nancy A. Remaley, MS; Frederick L. Ferris III, MD; Early Treatment Diabetic Retinopathy Study Research Group

Arch Ophthalmol. 1992;110(3):339-342.

Abstract
• The Early Treatment Diabetic Retinopathy Study, a randomized clinical trial supported by the National Eye Institute, was designed to assess the effect of photocoagulation and aspirin in 3711 patients with mild to severe nonproliferative or early proliferative diabetic retinopathy. Although the primary goal of the study was to evaluate the effect of photocoagulation and aspirin on diabetic retinopathy, the study also provided an opportunity to evaluate the effects of aspirin on the development of cataract. No evidence showed that aspirin use reduced the risk of development of cataract requiring extraction (4.1% vs 4.3% in patients assigned to aspirin or placebo treatment, respectively; Mantel-Cox P =.77; relative risk, 1.05; 99% confidence interval, 0.73 to 1.51). Aspirin use also did not reduce the risk of less extensive but visually significant lens opacities developing (29.6% vs 28.3%; Mantel-Cox P=.76; relative risk, 0.99; 99% confidence interval, 0.85 to 1.15). Early Treatment Diabetic Retinopathy Study results do not support the hypothesis that aspirin (at a dose of 650 mg/d) reduces the risk of cataract development in this diabetic population.

Author Affiliations
From the National Eye Institute, National Institutes of Health, Bethesda, Md (Drs Chew and Ferris and Ms Remaley); Michigan State Univeristy, East Lansing (Dr Williams); the Medical College of Wisconsin, Milwaukee (Dr Burton); and Maryland Medical Research Institute, Baltimore (Ms Barton).

Footnotes
Accepted for publication October 8, 1991.

Reprint requests to Biometry and Epidemiology Program, National Eye Institute, National Institutes of Health, Bldg 31, Room 6A-24, 9000 Rockville Pike, Bethesda, MD 20892.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Risk Factors for Incident Cortical and Posterior Subcapsular Lens Opacities in the Barbados Eye Studies
Hennis et al.
Arch Ophthalmol 2004;122:525-530.
ABSTRACT | FULL TEXT  

Aspirin Use and Risk of Cataract in Posttrial Follow-up of Physicians' Health Study I
Christen et al.
Arch Ophthalmol 2001;119:405-412.
ABSTRACT | FULL TEXT  

Effects of Aspirin on Vitreous/Preretinal Hemorrhage in Patients With Diabetes Mellitus: Early Treatment Diabetic Retinopathy Study Report No. 20
Chew et al.
Arch Ophthalmol 1995;113:52-55.
ABSTRACT  

A Prospective Study of Aspirin Use and Cataract Extraction in Women
Hankinson et al.
Arch Ophthalmol 1993;111:503-508.
ABSTRACT